FDA grants orphan designation to antifungal drug candidate CD101 IV

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted orphan drug designation to antifungal drug candidate CD101 IV, developed by Cidara Therapeutics Inc., for the treatment of candidemia and invasive candidiasis. The seven-year period of marketing exclusivity provided through orphan designation combined with an additional five years of marketing exclusivity provided from the previously announced QIDP designation gives CD101 IV for a...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login